Ultomiris (ravulizumab-cwvz) has been approved in Canada to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies…
Marisa Wexler, MS
senior science writer
Marisa Horak joined Bionews in 2018 right after she completed her master’s degree in cellular and molecular pathology. She has dedicated her career to making scientific and medical information more accessible to people affected by rare and chronic disorders.
Education
- MS, Cellular and Molecular Pathology, University of Pittsburgh
- BS, Microbiology, Michigan State University
Professional Accomplishments
- Universal concept signature analysis: genome-wide quantification of new biological and pathological functions of genes and pathways, 2019, Briefings in Bioinformatics
- Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity, 2018, Oncotarget
- Insights on processes of evolutionary tumor growth, 2016, Atlas Genet Cytogenet Oncol Haematol
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A new mathematical tool that combines factors such as age at disease onset, sex, and clinical test results, could predict…
Myasthenia Gravis News has brought you up-to-date coverage of the latest scientific research and developments in treatment related to…
An infection with parvovirus B19 may contribute to abnormal immune cell growth in people who have a thymoma, or thymus…
More than one in three people with myasthenia gravis (MG) have clinically relevant depression, and a similar proportion have…
CAN106, an investigational complement-inhibiting therapy being developed by CANbridge Pharmaceuticals, has been granted orphan drug designation by the U.S.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review applications seeking the…
The high blood sugar levels that characterize diabetes may prompt immune cells to be activated that can drive and worsen…
Telitacicept (RC18), an anti-inflammatory therapy developed by RemeGen, has been granted orphan drug designation by the U.S. Food and…
NMD670 safely improved muscle function and strength in a small clinical trial of people with myasthenia gravis (MG), the…